Search research articles
Contact Us
Filters
Showing results (21-30 of 125) with videos related to
Page
of 13
Sort By:
Acta Haematologica
|
March 15, 2013
Cross-talk between available guidelines for the management of patients with beta-thalassemia major
Khaled M Musallam, Michael Angastiniotis, Androulla Eleftheriou, et al.
Haematologica
|
December 20, 2011
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
Yesim Aydinok, Patricia Evans, Chantal Y Manz, et al.
Blood Reviews
|
February 20, 2018
A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
Maria Domenica Cappellini, John B Porter, Vip Viprakasit, et al.
Hemoglobin
|
February 9, 2016
Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update
Amelia Oliveira, Dana Warcel, Nancy Huntley, et al.
Critical Reviews in Oncology/Hematology
|
January 26, 2016
New insights into transfusion-related iron toxicity: Implications for the oncologist
John B Porter, Theo de Witte, M Domenica Cappellini, et al.
Blood
|
March 6, 2004
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
Bernard A Davis, Caoimhe O'Sullivan, Peter H Jarritt, et al.
Hemoglobin
|
December 10, 2008
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]
John B Porter, Ali T Taher, Maria D Cappellini, et al.
American Journal of Hematology
|
December 24, 2022
The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration
Maciej W Garbowski, Ioav Cabantchik, Chaim Hershko, et al.
British Journal of Haematology
|
March 18, 2014
High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major
Ratna Chatterjee, Rekha Bajoria, Farrukh T Shah, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
July 15, 2010
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
Patricia Evans, Reem Kayyali, Robert C Hider, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 125) with videos related to
Sort By:
Page
of 13
Acta Haematologica
|
March 15, 2013
Cross-talk between available guidelines for the management of patients with beta-thalassemia major
Khaled M Musallam, Michael Angastiniotis, Androulla Eleftheriou, et al.
Haematologica
|
December 20, 2011
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
Yesim Aydinok, Patricia Evans, Chantal Y Manz, et al.
Blood Reviews
|
February 20, 2018
A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
Maria Domenica Cappellini, John B Porter, Vip Viprakasit, et al.
Hemoglobin
|
February 9, 2016
Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update
Amelia Oliveira, Dana Warcel, Nancy Huntley, et al.
Critical Reviews in Oncology/Hematology
|
January 26, 2016
New insights into transfusion-related iron toxicity: Implications for the oncologist
John B Porter, Theo de Witte, M Domenica Cappellini, et al.
Blood
|
March 6, 2004
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
Bernard A Davis, Caoimhe O'Sullivan, Peter H Jarritt, et al.
Hemoglobin
|
December 10, 2008
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]
John B Porter, Ali T Taher, Maria D Cappellini, et al.
American Journal of Hematology
|
December 24, 2022
The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration
Maciej W Garbowski, Ioav Cabantchik, Chaim Hershko, et al.
British Journal of Haematology
|
March 18, 2014
High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major
Ratna Chatterjee, Rekha Bajoria, Farrukh T Shah, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
July 15, 2010
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
Patricia Evans, Reem Kayyali, Robert C Hider, et al.
Page
of 13